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Melanoma, a Tumor Based on a Mutant Stem Cell?
James M. Grichnik1,2, James A. Burch1, Ryan D. Schulteis1, Siqing Shan3, Jie Liu3, Timothy L. Darrow4,
Carol E. Vervaert4 and Hilliard F. Seigler4
Stem cells play a critical role in normal tissue maintenance, and mutations in these stem cells may give rise to
cancer. We hypothesize that melanoma develops from a mutated stem cell and therefore residual stem cell
characteristics should be able to be identified in melanoma cell lines. We studied three metastatic melanoma
cell lines that exhibited multiple morphologic forms in culture and demonstrated the capacity to pigment. We
used the ability to efflux Hoechst 33342 dye, a technique known to enrich for stem cells in many tissues, to
segregate cell populations. The cells with the greatest ability to efflux the dye were (1) small in size, (2) had the
capacity to give rise to larger cell forms, and (3) had the greatest ability to expand in culture. The small cells were
found to have a decreased proliferative rate and were less melanized. Large dendritic cells that appeared to be
nonproliferative were identified in cultures. Treatment with cytosine b-D-arabinofuranoside hydrochloride
(Ara-C) expanded the large cell population but the residual proliferative capacity, both in vitro and in vivo,
remained concentrated in the smaller cell fraction. Antigenic staining patterns were variable and
heterogeneous. Nestin (a neural stem cell marker) and gp100 (premelanosomal marker) favored the smaller
cell population, while nerve growth factor receptor often labeled larger cells. Morphologic and antigenic
heterogeneity remained intact after clonal purification. These findings are consistent with the behavior
expected for a tumor based on stem cell biology; this finding has diagnostic and therapeutic implications for
melanocytic neoplasias.
Journal of Investigative Dermatology (2006) 126, 142–153. doi:10.1038/sj.jid.5700017
INTRODUCTION
The epidermal melanocyte is currently thought to serve as the
origin for acquired benign and malignant melanocytic
neoplasias (Bennett, 2003; Hussein, 2004). A stepwise ‘‘de-
differentiation’’ process has been proposed for the develop-
ment of melanoma in which the mutated melanocyte passes
through benign nevus, dysplastic nevus, melanoma radial
growth, melanoma vertical growth, and metastatic melanoma
stages (Clark et al., 1984; Herlyn et al., 1985, 1987).
However, clinically, the majority of melanomas do not
evolve in pre-existing dysplastic nevi and many evolve in
normal appearing skin (Kelly et al., 1997; Lucas et al., 2003).
An alternative theory has been put forth (Cramer, 1984a, b),
suggesting that melanocytic neoplasias are derived from
immature melanocytic cells.
Immature melanocytic cells are present in normal human
epidermis (Grichnik et al., 1996), and melanocytic stem cells
have been identified in the murine hair follicle (Nishimura et
al., 2002). A growing body of literature has established the
role of stem cells in normal tissue homeostasis (Reya et al.,
2001; Brittan and Wright, 2002; Alonso and Fuchs, 2003).
Stem cells are slowly proliferative cells that give rise to more
rapidly proliferative cells (transiently amplifying (TA) cells)
that eventually fully differentiate into mature tissue compo-
nents. Although much remains to be understood about
normal melanocyte turnover, it is reasonable to assume that
melanocytes in the human skin are normally replenished
from a reservoir of immature cells. This is supported clinically
by (1) disease processes such as vitiligo where differentiated
melanocytes are destroyed, but when the disease is con-
trolled, new melanocytes appear (Yu, 2002), and (2) hair
cycling experiments where hair bulb melanocytes appear to
undergo apoptosis but are replenished by melanocytic cells
in the outer root sheath, with hair regrowth (Tobin et al.,
1998; Nishimura et al., 2002; Botchkareva et al., 2003).
Since cells with the capacity to proliferate and differentiate
into melanocytes exist in the skin, their role should be
considered in our models of melanocytic neoplasia.
Evidence continues to mount for the role of stem cells in
cancer (Reya et al., 2001). Cells with stem cell-like features
have been identified in a number of human malignancies
(Wulf et al., 2001; Al-Hajj et al., 2003; Singh et al., 2003;
Kondo et al., 2004). Leukemia lines have been noted to
include cells with stem cell-like features (Wulf et al., 2001).
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Breast cancer stem cells have been identified through
expression of a unique set of cell markers and have been
shown to have the greatest potential to form tumors in an
animal system (Al-Hajj et al., 2003). Glial tumor stem cells
have been shown to have the capacity to differentiate into
both glial and neuronal cell forms (Kondo et al., 2004).
Theoretically, if mutational events occur in stem cells giving
rise to melanocytic neoplasias, then it is reasonable to assume
that these mutated cells would attempt to continue to follow
normal differentiation pathways until they accumulated
sufficient genetic damage that this was no longer possible.
However, if the mutational events occur in mature melano-
cytic cells, the resulting tumor cells would be expected to be
more aggressive than the original cell and expand in a
homogeneous manner until additional mutations created new
clones that would then repeat the clonal selection process.
We hypothesize that the mutagenic event that gives rise to
melanoma occurs within a stem cell and not within a
differentiated melanocyte. In the following experiments, we
will demonstrate that melanoma tumors exist that have
characteristics that are consistent with a tumorigenesis event
based on a mutant stem cell.
RESULTS
Metastatic melanoma lines stably maintain multiple morphol-
ogies
Given the hypothesis that melanomas are derived from
mutant stem cells, it should be possible to identify cell lines
that retain residual characteristics of this population. We
selected three cell lines from our collection, DM1N, DM2N,
and DM3N, that appeared to be good candidates for the
discrimination of stem-cell-like properties (Figure 1). All three
cell lines were originally isolated from lymph node melano-
ma metastases. Microscopic examination revealed cells with
different morphologies including small ovoid, spindle, flat
polygonal, and large dendritic forms (Figure 1a, c, and e).
Multinucleated cells were also noted. These multiple cell
morphologies persisted, despite more than 1 year of
continued passage in culture. Visible melanin production
was increased if the cells were maintained under confluent
conditions (Figure 1b, d, and e). Tumor cell spheroids also
developed under confluent conditions. Lines DM1N and
DM3N increased pigmentation readily once confluent, and
DM2N required longer-term cultures.
The very existence of melanoma lines that retain the
capacity to pigment and exhibit multiple cell forms in culture
despite continued passage supports the concept of an origin
based on a stem cell lineage. These cell lines were then used
for further investigation.
Hoechst dye-low cells are small in size, give rise to larger cell
forms, and have a growth advantage in mixed culture
We sought an experimental approach that would allow for
separation of the larger and smaller cell forms. One of the
approaches was to use Hoechst dye efflux. The active efflux
of a vital dye, Hoechst 33342, has been shown to identify a
dye-low population of cells (side population) enriched in
stem cells in the bone marrow (Goodell et al., 1996), in other
tissues (Asakura and Rudnicki, 2002), and in some tumor cell
lines (Kondo et al., 2004). In neonatal foreskin, this technique
has also revealed a rare subpopulation of melanocytic cells
(Terunuma et al., 2003).
The flow cytometry plot of Hoechst dye fluorescence in
the blue and red revealed a continuum of cells ranging from
dye-low to dye-high components for the three melanoma
lines. Overlying the primary collection of cells was a faint
secondary collection of cells (separation between the two cell
masses is indicated by the white arrows in Figure 2). DNA
content analysis revealed that the upper cell mass had
increased DNA content consistent with cells in the S/G2/M
stages of the cell cycle (data not presented). The dye-low cells
in most tissues demonstrate sensitivity to verapamil but some
tissues, such as brain (Asakura and Rudnicki, 2002), have
resistant subpopulations. Verapamil was noted to inhibit the
ability to efflux the dye, with the three lines exhibiting
differential sensitivity with a 33, 81, and 100% decrease in
the gated dye-low population for DM1N, DM2N, and
DM3N, respectively (Figure 2b, d, and f).
Cells with the greatest ability to efflux the Hoechst dye
(dye-low cells) were isolated and found to be small in size.
Culture of these small cell forms, in dilute conditions,
revealed slow growth with the eventual appearance of larger
cell forms (Figure 3).
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Figure 1. Metastatic melanoma cells give rise to heterogeneous cultures.
Metastatic melanoma cell lines DM1N (a, b), DM2N (c, d), and DM3N (e, f)
are shown. Despite passage for over a year, the cultures remain hetero-
geneous, displaying both small and large cell forms (a, c, e). Bar¼ 50mm. In
subconfluent culture, these tumors are primarily nonpigmented (left tube; b,
d, f) but with increasing confluence, pigmentation becomes more apparent
(right tube; b, d, f).
www.jidonline.org 143
JM Grichnik et al.
Melanoma Stem Cells
In order to study the contribution of these dye-low cells to
overall culture growth, we stably labeled duplicate cultures
of the three lines with green fluorescent protein (GFP) using a
lentivirus system. Together with the original unlabeled
cultures, this allowed us to study the impact of individual
cells within the larger population through mixing experi-
ments. We isolated GFP-labeled cells from the dye-low and
dye-high regions of the primary population of Hoechst dye-
stained cells, further purified by resorting a second time, and
introduced them into nonsorted, nonlabeled cultures of the
same tumor type (Figure 4). At 24 hours, the introduced cells
had expanded beyond their original dye-low and dye-high
compartments (Figure 4e and f). The total percentage of GFP
cells was similar for the dye-low and dye-high mixed
cultures on day 1 (Figure 4g and h, green line). The dye-
high cultures rapidly lost cells in the dye-high compartment
(Figure 4h, blue line) and equilibrated to approximately equal
percentages of GFP cells in all the compartments (Figure 4h,
red, blue, and green lines) within 1 week. In contrast,
the percentage of dye-low GFP cells (Figure 4g, red
line) increased in the dye-low cultures and equilibrium
was not achieved for months. The dye-low cells led to a
greater increase in the overall percentage of GFP cells
with a maximum of 1.8-, 2.6-, and 4.7-fold over the
dye-high cells for DM1N, DM2N, and DM3N, respectively.
At extended time points, GFP-positive cells decreased.
It is not entirely clear why this occurred, but it was a
repeatable phenomenon, potentially due to either GFP
toxicity, GFP downregulation, or a GFP expression selection
basis.
Small cells exhibit a lower proliferative rate
The delayed equilibrium of the dye-low cells as compared to
the dye-high cells suggested a difference in proliferative rate.
As the dye-low cells were small in size and the dye-high cells
were large, these size differences allowed us to evaluate
proliferation differences directly in culture. For these experi-
ments, we labeled cells actively synthesizing DNA during a
90-minute period with BrdU. Nuclear size appeared to
correlate with overall cell size and BrdU incorporation was
noted in the nuclei of both small and large cells (Figure 5).
The cells were imaged (100–200 cells per field) and nuclei
scored as large or small based on a template designed to split
the population roughly in half (data are presented 7SD of
nuclear counts for four representative microscopic fields).
The nuclei were segregated into either small or large
categories, with 4975, 6178, and 5974% of the nuclei
considered small in DM1N, DM2N1, and DM3N, respec-
tively. The data for the BrdU incorporation are presented
graphically in Figure 5d. Large cells were found to be actively
synthesizing DNA at approximately twice the rate of the
small cells.
To further verify the difference in proliferation between the
cell sizes, we segregated the cells on the basis of low and
high content of a vital cytoplasmic dye, cell tracker orange
(CTO). Unlike the DNA staining Hoechst dye, the CTO dye
is independent of DNA amount. This method was very
effective in segregating the small and large cell populations
(Figure 6). The large cell population included heavily
melanized large dendritic cells (Figure 6). DNA quantifica-
tion analysis revealed S/G2/M to G1/G0 ratios of 11.9,
51.4, and 19.3% for the total population, 2.8, 15.6, and 9.5%
for the small cell fraction (smallest 5%) and 43.8, 70.4, and
47.5% for the large cell fraction (largest 5%) respectively
for DM1N, DM2N, and DM3N. This confirmed marked
differences in the proliferative rates between the small and
large cells.
One concern was whether the difference in proliferative
rate could be largely due to the dynamics of cell division,
with small cells having to grow to large cells before division.
To address this concern, we mixed small and large CTO-
labeled cell fractions with unsorted GFP cells and followed
the cultures. At 48 hours, dividing cells could be identified for
both small and large cell forms (Figure 7). Therefore, small
Hoechst Red
H
oe
ch
st
 B
lu
e
a b
c d
e f
D
M
1N
D
M
1N
D
M
2N
D
M
2N
D
M
3N
D
M
3N
+ VerapamilControl
P4 P4
P4P4
P4 P4
Figure 2. Metastatic melanomas exhibit a gradient of capacity to efflux
Hoechst 33342 dye and variable sensitivity to verapamil. Metastatic
melanoma cell lines DM1N (a, b), DM2N (c, d), and DM3N (e, f) were
incubated with Hoechst 33342 and analyzed for Hoechst dye emission in the
blue (Y-axis) and red (X-axis). All three lines exhibited a gradient of cell
staining with a break point (indicated by an arrow in a, c, e) between a lower
comma-like structure and an overlying corona of cells (cells above this arrow
were found to include cells in S/G2/M). The cells with the least amount of
Hoechst 33342 staining are highlighted by the purple triangle (a, c, e).
Incubation with verapamil resulted in mild, moderate, and marked loss
of the lightest staining cells for DM1N (b), DM2N (d), and DM3N (f)
respectively.
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cells are not merely the progeny of large cells, requiring
growth to a larger cell size before division can recur.
These mixed cultures were followed for approximately 3
months with flow cytometry to identify whether segregation
by the CTO dye would also reveal differences in the overall
contribution of the small and large components to tumor
growth. The small cell component demonstrated a 2.2-, 5.9-,
and 2.0-fold maximum increase over the large cell compo-
nent for DM1N, DM2N, and DM3N, respectively.
These efforts demonstrated that the small cell component
is less proliferative than the large cell component but, despite
this, it retains a greater capacity to expand in culture.
Melanoma lines display antigenic heterogeneity
Given the heterogeneous cell morphology, it was of interest
to determine whether the lines would be found to be
antigenically heterogeneous and whether antigenic markers
segregated with small or large cell forms. At the outset, it
became clear that these cultures were antigenically very
dynamic. Major factors influencing this appeared to
include tissue culture surface, media change rate, cell
density, and duration in culture. Confluent cultures seemed
to be the most stable and were used for the experiments
presented. Mechanically detached cells for the three lines
were double labeled with Nestin/gp100 and nerve growth
factor receptor (NGFR)/gp100 (Figure 8). Overall, nestin
and gp100 favored the smaller cell population while NGFR
often labeled larger cells. A few nestin-positive cells with
very bright staining were noted that did not also coexpress
high levels of gp100. Cells were also noted in the culture
system that failed to stain for either antigen (Figure 8a, c,
and e). Heterogeneous staining was also noted for Mart-1,
smooth muscle actin, and KIT (present on DM2N) (data not
shown).
Terminally differentiated large dendritic cells can be identified
and this population can be expanded with Ara-C treatment
In order for the small cells to contribute to a greater extent to
the tumor bulk, the larger cells must eventually cease
proliferation and be lost from the tumor environment. In an
effort to identify cells that had ceased proliferation, we
labeled the cells with the CTO dye and followed the cultures
over time. The dye was progressively diluted in the cells
undergoing cell division. After 6 days, most of the cells in the
culture had diluted the dye and a subpopulation of brightly
staining large dendritic cells was revealed (Figure 9). Lacking
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Figure 3. Small cell forms appear to have the capacity to give rise to heterogeneous populations of cells. Hoechst dye-low DM1N (a, b, c), DM2N (d, e, f), and
DM3N (g, h, i) metastatic melanoma cells were isolated by flow cytometry sorting, found to be small in size, and were followed in culture. Photomicrographs are
of representative regions of the cultures at 2 hours (a, d, g), 5 days (b, e, h), and 12 days (c, f, i). Bar¼ 50 mm.
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evidence of further cell division, these cells were interpreted
as terminally differentiated.
These terminally differentiated cells were rare and we
sought mechanisms to expand this subpopulation in order to
further study the subgroup of cells. In order to accomplish this
task, we utilized a DNA synthesis inhibitor, cytosine b-D-
arabinofuranoside hydrochloride (Ara-C). Cultures treated
with Ara-C for 3 days retained 3774, 270.2, and 3873% of
the total number of cells present in matched control cultures,
for DM1N, DM2N, and DM3N, respectively. The majority of
the retained cells in the Ara-C-treated cultures were of greater
size and dendricity than the cells in the nontreated control
cultures. The Ara-C-treated and normal control cells were
trypsinized, concentrated, and replated. At 1 day after the
plating, the normal control cells had 9274, 8577, and
12274% of the plated counts and, on day 7, these cells had
expanded to 1,520780, 2,0267201, and 1,6957150% of
the plated cell numbers. In contrast, the Ara-C-treated cells
had 4374, 3171, and 6475% of the plated counts on day 1
and revealed a modest decline with 3276, 1471, and
5678% of the plated cell numbers remaining at day 7. Thus,
the large dendritic differentiated cells in the Ara-C-treated
cultures persisted but did not appear to proliferate and were
slowly lost from the culture environment as would be
expected for terminally differentiated cells. However, with
longer culture times, colonies of smaller cell forms began to
become apparent, suggesting that there was a subpopulation
of cells that had survived the Ara-C treatment.
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Figure 4. Small cell forms slowly expand in culture and contribute to a greater extent to overall cell growth. The experiment shown is of the DM3N cell line.
Small dye-low (triangular region –lower left) and large dye-high (polygonal region –right) GFP-labeled melanoma cells were segregated by flow cytometry based
on Hoechst dye staining (a). The purified GFP-labeled dye-low cells (b) and dye-high cells are shown (c) after two cycles of cell sorting. Both groups of these cells
were mixed with native tumor cells and the cultures analyzed initially after 24 hours. The flow cytometry plot (d) illustrates the Hoechst dye staining of the entire
dye-low mixed culture at 24 hours. The dye-high mixed culture was essentially identical (not shown). Display of the GFP-positive cells in the dye-low mixed
culture (e) and the dye-high mixed culture (f) at 24 hours revealed a redistribution of cells from their original position (b, c). Despite this redistribution,
more dye-low cells (triangular gate at the lower left) and more dye-high cells (gate on the right) were retained in respective cultures. The charts depict
GFP-positive cell concentrations over time of the dye-low (small cell) (g) and the dye-high (large cell) (h) mixed cultures. The green line ( ) is the overall
percentage of GFP-positive cells in the mixed cultures. The red line ( ) is the percentage of GFP-positive cells in the dye-low gated population. The blue line ( )
is the percentage of GFP-positive cells in the dye-high gated population.
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Residual growth capacity remains concentrated in the small cell
compartment after treatment with Ara-C
In order to demonstrate that residual proliferation capacity
was retained in a resistant subpopulation of small cells and
was not due to ‘‘de-differentiation’’ of the large dendritic cell
forms, we segregated the small and large cell populations and
followed them for growth capacity both in vitro and in vivo.
DM1N and DM3N were treated continuously with Ara-C for
5 days. Owing to toxicity, DM2N was given normal media on
days 3 and 4. The treated cultures were allowed 1 day to
recover in normal media (day 6) before cell sorting. The cells
were stained with CTO and were sorted into large (CTO-high)
and small (CTO-low) cell fractions.
For the in vitro experiments, the sorted small and large cell
fractions were plated at equal numbers, followed in culture,
and harvested together when sufficient cell numbers had
recovered (Figure 10a–f). Compared to the large cell
component, the small cell component included the vast
majority of cells with growth potential (Figure 10, right
panel), suggesting that recovery was occurring from resistant
small cells and was not due to ‘‘de-differentiation’’ from the
larger cell forms.
We also chose to verify that this phenomenon occurs in
vivo, by utilizing a murine window system in which cells can
be injected and followed (Shan et al., 2004). For these
studies, Ara-C-treated, GFP-labeled cells, sorted into CTO-
low (small cell) and CTO-high (large cell) populations, were
used. For DM3N, there were three surviving mice with CTO-
low injected windows and four with CTO-high injected
windows. Two of the three CTO-low grafts retained cells
while only one of the four CTO-high grafts retained cells.
DM3N CTO-low and CTO-high grafts with retained cells are
presented (Figure 11). At day 4, the retained injected DM3N
GFP-labeled cells were relatively equivalent, but by day 21,
the CTO-high (large cell fraction) diminished in size, while
the CTO-low (small cell fraction) expanded. Transillumina-
tion demonstrated pigment deposition at the large cell (CTO-
high) injection site and an amelanotic tumor mass at the small
cell (CTO-low) injection site. Treated cells from the other
two lines largely failed to survive in the window system,
suggesting a need for further understanding of the effect of the
murine environment on the human tumor cell lines, and the
need to further optimize the cell treatment protocol. Never-
theless, the results with the DM3N cell line suggest that it is
possible to segregate fractions of cells from melanoma tumors
that have different tumor-forming capacities.
Purified single tumor cells retain capacity to give rise to
heterogeneous cultures
If the tumor is based on a mutant stem cell, then the
heterogeneous characteristics should be maintained in
cultures established from a single tumor cell. If the tumor is
based on a ‘‘de-differentiation’’ process and heterogeneity is
due to accumulation of different mutant clones, then single-
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Figure 5. Cells with smaller nuclei exhibit a decreased fraction of nuclei
incorporating BrdU. Melanoma lines DM1N (a), DM2N (b), and DM3N (c)
were labeled with BrdU for 90 minutes and evaluated immunohistochemi-
cally. Small and large nuclei were noted to be positively stained. Bar¼ 50 mm.
Cell nuclei were segregated into small and large subcategories and scored.
The graph (d) reveals the findings, with total percentage of BrdU (þ ) nuclei in
gray, percentage of small nuclei in striped, and percentage of large nuclei in
black. Error barsþ SD.
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Figure 6. Large, more melanized cell forms can be efficiently segregated
from small cell forms on CTO fluorescence. Confluent cultures of DM1N
(a, b), DM2N (c, d), and DM3N (e, f) were labeled with CTO and the lowest
5% (a, c, e) and highest 5% (b, d, f) of cells were isolated, cultured on glass
slides until adherent (24 hours for DM1N and DM3N, and 48 hours for
DM2N), and stained with Fontana-Masson to highlight the melanin content.
Bar¼50 mm.
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cell cloning should initially give rise to a uniform cell
population. We sought to clone each line from a single cell
but unfortunately found that single cells do not survive well
on their own. We utilized our GFP-labeled tumor cells to
overcome this hurdle. Non-GFP-labeled cells for each tumor
line were sorted into 96-well plates (30 cells per well) as
feeder cells. This was followed by the introduction of a single
GFPþ cell (matched for the specific tumor line, sorted from
the whole culture based on adequate GFP signal) into each
well. The majority of cells failed to survive, resulting in only
scattered positive wells often with only one obvious colony.
GFP-positive colonies were expanded. These colonies were
then subjected to flow cytometric purification, to exclude
possible contaminating non-GFP cells. The resultant lines,
expanded from a single GFP-labeled melanoma cell, are
illustrated (Figure 12) and were found to retain the ability to
sustain multiple morphologic forms. These cells also retained
the ability to pigment at higher densities and exhibited
antigenic heterogeneity (data not presented).
DISCUSSION
These studies were undertaken to determine if residual stem
cell characteristics could be identified in metastatic melano-
ma cell lines. We have identified metastatic melanoma cell
lines that are heterogeneous, both in cell morphology and
antigenic characteristics even after long-term culture and
single-cell cloning. Within these cultures, we have identified
smaller cells that are Hoechst 33342 dye-low and have the
capacity to give rise to larger cell morphologies. Despite a
slower proliferative rate of the small cell population, these
cells demonstrated an increased capacity to drive cellular
expansion in culture. Larger dendritic, pigmented, nonproli-
ferative cell forms could be identified and expanded in the
presence of Ara-C. These findings are consistent with the
biologic processes that would be anticipated for a tumor
based on a mutant stem cell attempting to undergo normal
developmental processes.
The metastatic melanoma cultures were found to include
cells with different morphologies including small ovoid,
bipolar, flat polygonal, and large dendritic forms. These
features were maintained even after single-cell cloning. This
is consistent with a mutated cell attempting to follow normal
melanocytic developmental pathways. Similar cell morphol-
ogies including small nonpigmented and larger pigmented
forms have been noted in primary cultures of murine
melanocytic cells (Sviderskaya et al., 1995). In human skin,
at least three different phenotypic stages of melanocytes can
be identified in hair follicle studies, including nonpigmented
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Figure 7. Small cells and large cells have the capacity to divide in culture.
Melanoma lines DM1N (a, b), DM2N (c, d), and DM3N (e, f) were labeled
with CTO and the lowest 5% (a, c, e) and highest 5% (b, d, f) of cells were
isolated and mixed with nonsorted GFP-labeled cells of the same tumor type
and followed. At 48 hours, ‘‘doublets’’ of cells became apparent. White
barbells link CTO-labeled cell doublets (orange) and yellow barbells link
GFP-labeled cell doublets (green). Bar¼ 100 mm.
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Figure 8. Cells from confluent cultures demonstrate heterogeneous
antigenic staining with neural stem cell and melanocytic markers. DM1N (a,
b), DM2N (c, d), and DM3N (e, f) cells were mechanically detached from
post-confluent cultures and labeled with antibodies against nestin (red) and
gp100 (green) (a, c, e) and antibodies against NGFR (red) and gp100 (green)
(b, d, f). Nuclear staining is shown in blue. While colocalization of the
markers could be noted, many of the brightly staining cells for nestin and
NGFR did not colocalize with gp100. Phase-contrast light is also included in
the left panel of photomicrographs (a, c, e) to highlight the presence of cells
not labeling for either antigen. Bar¼50 mm.
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and pigmented proliferative cell forms as well as heavily
pigmented nonproliferative cell forms (Tobin and Bystryn,
1996). Thus, the continued formation of differentiating cell
forms is consistent with normal developmental biology.
The Hoechst dye studies allowed us to segregate small and
larger cell forms. The populations best at effluxing the
Hoechst dye have been noted to be enriched for stem cell
capacity (Goodell et al., 1996). The ability of cells to efflux
the Hoechst dye is thought to be primarily due to the activity
of ATP-binding-cassette transporters (Zhou et al., 2001). In
the literature, the dye-low population is generally presented
as a minor group of cells (termed side population) projecting
from a larger mass of cells and extending toward the origin on
the flow cytometry plot. In our experiments, the bulk of the
cultured cells appeared to form this structure. Verapamil
sensitivity is often used to confirm this population by
inhibiting the cell’s ability to efflux the dye. All three lines
demonstrated sensitivity to verapamil, with DN3N demon-
strating a marked response, DM2N a moderate response, and
DM1N a mild response. It has been noted that some tissues
such as brain (Asakura and Rudnicki, 2002) have verapamil-
resistant subpopulations. It is possible that the different
response levels seen in our lines are due to differences in
the transporters expressed. Melanoma appears to be unusual
in the amount of cells capable of effluxing the Hoechst dye,
and it is possible that melanoma includes a larger percentage
of stem-cell-like cells than other tumors studied (Kondo et al.,
2004). In support of this possibility, nuclei from melanoma
cells were found to be able to give rise to embryonic stem
cells that were then able to differentiate into melanocytic,
lymphocytic, and fibroblastic cells in nuclear transplantation
studies (Hochedlinger et al., 2004). Nuclei transplanted from
leukemia, lymphoma, and breast cancer cells failed to give
rise to embryonic stem cells.
The melanoma cells with the greatest Hoechst efflux
capacity were small in size and gave rise to larger cell forms.
The small cells were also found to have a decreased
proliferative rate compared to the larger cells (lower
percentage of BrdU-positive nuclei and DNA profiles with
decreased percentage of cells in S/G2/M phases of the cell
cycle) and were found to be fully competent of cell division
(not just recently divided large cells). The differences in
proliferative rate are consistent with stem-cell to transient-
amplifying-cell biology. It is notable that an increased
proliferative rate has been reported for pigmented melano-
cytes compared to the nonpigmented melanoblast population
from which they were derived (Sviderskaya et al., 1995).
Differences in cell size may be dependent of the type of cell
the tumor is ultimately attempting to differentiate toward. A
small size for stem cells has been reported for hepatic stem
cells and glioma cells (Xiao et al., 2003; Kondo et al., 2004).
The small cells also had the greatest ability to expand in
culture, but this was a slow process requiring months instead
of days. This phenomenon was consistent with the behavior
that would be expected for a stem-cell-based system
requiring the more rapidly proliferative cells to ultimately
terminally differentiate and be lost from the system before
being replaced by progeny of the underlying stem cell
compartment. The CTO dilution studies indicated that
nonproliferative large dendritic cells were present in the
culture system but were relatively rare. This may explain why
the difference obtained between the small and large cell
compartments in the untreated cells was only two- to five-
fold. In addition to a paucity of differentiated cells, there may
also be some capacity for cells in the TA population to return
to stem cell status. In support of this concept, melanocyte
stem cells have been shown to give rise to TA cells and some
of those TA cells appeared to be able to revert to stem cells
(Nishimura et al., 2002). The Hoechst dye experiments were
able to give us some insight into the process. It is of interest
that in the experiments in which we added GFP-labeled dye-
high cells, some of these cells appeared to repopulate the
dye-low region. Thus, some cells appear to have some
capacity to interconvert between cell states. However, cells
also appear to cross a threshold and terminally differentiate.
This is supported by the Ara-C experiments. Sorting of the
treated cultures revealed dramatic differences in the growth
capacity between small and large cell compartments. Taken
together, these experiments suggest that under the normal
D
M
1N
D
M
1N
D
M
3N
D
M
3N
D
M
2N
D
M
2N
6 days post CTO labeling
a
b
c
Figure 9. Large dendritic cells are present in cultures that appear to be
nonproliferative owing to the retention of CTO dye. Melanoma lines DM1N
(a), DM2N (b), and DM3N (c) were labeled with CTO and followed in culture
over time. The CTO dye was progressively lost from the majority of the cells
but the staining persisted in scattered large dendritic cells (arrows). These
images were taken 6 days after CTO labeling. Bar¼ 100mm.
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culture conditions, the majority of melanoma cells are in the
stem cell/TA state and that some interconversion between the
states is possible. Eventually, the cells terminally differentiate
and are lost from the system, allowing the stem cell
compartment to expand.
Ideally, antigenic markers will be identified that will
detect the most stem-cell-like melanoma cells. However, as
melanocytes have been derived from embryonic stem cells
(Yamane et al., 1999), neural crest cells (Kawa et al., 2000;
Kawakami et al., 2002), and melanoblasts (Sviderskaya et al.,
1995), these markers could lie anywhere along the develop-
mental pathway and may be different for different melanoma
tumors. More primitive pluripotent stem cells may have
mutations that favor the melanocytic pathway, but the tumor
stem cell itself may have greater latitude in the type of
cellular pathways it can activate, allowing for more plasticity
and potentially a more aggressive tumor. This hypothesis
could account for findings such as vascular mimicry in
aggressive melanoma tumors (Hendrix et al., 2003). For the
three lines in this study, the staining patterns were found to be
dynamic and varied, dependent on the culture conditions.
We presented data from confluent cultures, speculating that
the confluent conditions would be most similar to the in vivo
tumor environment (high cell-to-cell interaction and auto-
crine/paracrine factor levels). Of the markers studied, NGFR
was the one most likely to be found on the larger cell forms.
The pre-melanosomal marker gp100 was variably expressed
favoring the smaller cell forms. Similar findings were also
noted for mart-1. The most interesting finding centered on the
neural stem cell marker, nestin. This marker has been
reported to be a marker of pluripotent stem cells (Wiese et
al., 2004). While colocalization with the pre-melanosomal
marker was noted, the cells staining most intensely for nestin
had very little obvious gp100. While it is tempting to
speculate that these brightly staining nestin-positive cells
are the melanoma tumor stem cells, the high degree of
staining variability, including some circumstances in which
they are virtually absent, suggests that we need a better
understanding of the dynamics and control of environment
before we can fully elucidate its value. The presence of nestin
staining opens the door for the evaluation of a vast number of
potential markers to further elucidate the stem cell biology of
melanoma tumors.
There are several attractive features of the stem cell
hypothesis for melanocytic neoplasia. First, melanocytic nevi
and melanoma would both have a common origin, being
derived from a genetically defective stem cell. The severity of
the defect in growth regulation would determine the extent of
overgrowth; self-limiting defects would be benign, while
nonlimiting defects would be malignant. An additional
mutation could occur during the evolution of a benign
neoplastic process, resulting in a malignant subclone, but this
would not be required. Second, the concept of ‘‘de-
differentiation’’ could be retired. Rather than melanoma
‘‘de-differentiation’’ from a melanocyte, the gross perception
of de-differentiation could merely be due to the unmasking of
a malignant stem/precursor cell with decreased ability to
produce competent differentiated daughter cells. Third,
metastasis could be based on the more primitive stem cell
biology, which may include its small size and differences in
cell adherence. Fourth, delayed onset and tumor dormancy
may be more easily explained. Cells could exist unstimulated
for long periods in the body, and then when environmental
conditions are appropriate, the mutated stem cells could
again give rise to TA/differentiating daughter cells and the
tumor would become apparent. Fifth, death from melanoma
despite a strong immunologic response to melanocytic
antigens can also be more easily explained. While the
daughter cells might be easily destroyed by the immune
system, the malignant stem-like cells might be overlooked.
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Figure 10. Ara C treatment increased the percentage of large dendritic cell forms while growth capacity was primarily retained in the smaller cell fraction.
Panels illustrate DM1N (a, d), DM2N (b, e), and DM3N (c, f) treated with Ara-C, segregated into large (a–c) and small cell forms (d–f) based on CTO staining
photographed at 24 hours. Bar¼ 50mm. Equal portions of these cells were plated in culture and followed over time. The majority of cells eventually died and
detached from the plate in both subgroups. Scattered colonies of surviving cells were more frequent in the small cell cultures. (g) The graph illustrates cell
number differences between the CTO-high (large) cells (gray) and the CTO-low (small) cells (black). The cell lines grew at different rates and were harvested
when sufficient cells numbers were present but still subconfluent; the data shown are for DM1N at 2 weeks, DM3N at 3 weeks, and DM2N at 7 weeks. Error
barsþ SD.
150 Journal of Investigative Dermatology (2006), Volume 126
JM Grichnik et al.
Melanoma Stem Cells
Thus, a number of known biologic characteristics of
melanomas support the theory that they may have originated
from a mutated stem cell.
In summary, we believe that the stem cell model is
consistent with our clinical knowledge of melanoma and
normal biology and inconsistent with ‘‘de-differentiation’’.
This stem cell model has diagnostic, prognostic, and
therapeutic ramifications.
MATERIALS AND METHODS
Cell lines and culture
Melanoma cells were obtained from patients’ lymph node metas-
tases under IRB-approved protocols (HFS). Three metastatic mela-
noma lines were selected for study and referred to as DM1N, DM2N,
and DM3N. The cell lines were maintained in MEM (supplemented
with 2 mM L-glutamine, antibiotic-antimycotic, and 5% fetal bovine
serum) in Costar vented Tissue Culture flasks (Corning, New York,
NY) at 371C in a humidified 5% CO2 environment. Media were
changed every 48 hours. All tissue culture reagents were obtained
from Gibco (Grand Island, NY). Ara-C (Sigma, St Louis, MO) was
used at a final concentration of 200 mM. Cell counting was performed
on hematocytometer and error reported as the standard deviation
between three separate manual counts. In order to control for
potential differences in the phenomena under study, we utilized
three different melanoma cell lines. The data presented for each of
the three lines represent single experiments, not averages of triplicate
experiments.
Flow cytometry
Flow cytometry with Hoechst 33342 was undertaken in a manner
similar to that previously described (Goodell et al., 1996), with a few
modifications. Briefly, cells were trypsinized from flasks and
resuspended to a concentration of 1 106 cells/ml in media
containing 2.5 mg/ml Hoechst 33342 (Sigma) and maintained at
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Figure 11. The small cell component of Ara-C-treated DM3N reveals
amelanotic tumor growth in nude mice. GFP-labeled DM3N cells were
treated with Ara-C and sorted into small and large cell forms based on CTO
dye content. Small (a, c, e, g) and large (b, d, f, h) cells, 40,000 in 40 ml, were
injected into nude mouse skin and visualized through a glass window at day 4
(a, b), day 7 (c, d), and day 21 (e, f) for GFP-positive cells. At day 21, the small
cell component had given rise to an enlarging mass (e) while the large cell
component had decreased in size (f). Transillumination was performed at day
21 (g, h), revealing a well-vascularized amelanotic tumor arising from the
small cell component and the presence of pigmentation at the location of the
injected large cell component. Bar¼200 mm.
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Figure 12. Heterogeneity is retained in single cell purified melanoma lines.
The photomicrographs are of cells expanded from a single GFP (þ ) cell from
each of the cell lines (a, DM1N; b, DM2N; c, DM3N). These cultures
continued to demonstrate the presence of heterogeneous cell forms.
Bar¼50 mm.
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371C for approximately 90 minutes prior to analysis. For the
verapamil-sensitivity experiments, verapamil 50 mM (Sigma) was also
included. Immediately prior to analysis, 2 U DNase 1 (Sigma) was
added to prevent cell clumping along with 1 mg/ml propidium iodide
(Sigma) to allow the exclusion of dead cells. Cells were analyzed on
a FACSVantage SE with Diva Option cell sorter (BD Biosciences, San
Jose, CA) and the data processed using FACS Diva software. Cells
were excited at 350 nm (secondary laser) and Hoechst Blue emission
was detected using a 450/20 nm filter and Hoechst Red using a 675
long-pass filter. For the cell labeling with cell tracker orange
(100 nM; Molecular Probes Inc., Eugene, OR), CTO was added
directly to the media and incubated for 30 minutes prior to
trypsinization. CTO-labeled cells were excited at 488 nm and
emission detected with a 575/26 nm filter. GFP-labeled cells were
excited at 488 nm and emission detected with a 530/30 nm filter. For
DNA quantification, cells were sorted into a solution including NP-
40 (0.1%; Sigma), Propidium iodide (40 mg/ml), and ribonuclease A
(20 mg/ml; Sigma) and analyzed by flow cytometry (excited at
488 nm and emission detected with a 667/30 nm filter) and
processed using Cell Qwest software (BD Biosciences). Standard
deviation was based on the number of events counted. For this
instrument, the percentage standard deviation for 185, 370, 700,
1,400, 1,850, and 7,000 events was 10.1, 9.2, 5.3, 1.6, 0.6, and
0.4%, respectively. An average of 50,000 total events were counted.
GFP labeling of the tumor lines
Tumor cells were transduced using an EGFP (enhanced GFP)
lentiviral system. The plasmids were a generous gift from Bryan R.
Cullen PhD (Lee et al., 2003). The infective particles were produced
by co-transfecting plasmids pNL-SIN-EGFP (2.0 mg), pcRev (100 ng),
pcTat (100 ng), and pHIT/G (50 ng) in the presence of FuGENE 6
(Roche Diagnostics, Basel, Switzerland) into 5 105 293T cells in
each well of a six-well plate coated with poly-L-lysine (BD
Biosciences). The media were changed after overnight incubation
and 48 hours later the GFP lentivirus-containing media were sterile
filtered (0.45mm; Corning) and transferred to 5 105 DM1N,
DM2N, and DM3N cells also plated in a six-well plate. After
24 hours and again after 48 hours, the media were changed and the
GFP-expressing cells were isolated on day 3 by FACS. Thereafter, the
cells were carried in culture under similar conditions as those of the
nontransduced lines.
BrdU staining of cultured melanoma cells
Cells cultured on 24 mm Thermox tissue culture coverslips were
treated with 10 mM BrdU for 90 minutes, fixed with 70% EtOH for
20 minutes, incubated in 2.5 N HCl for 3 hours, and then neutralized
in TBE, pH 8.0, for 5 minutes. Incorporated BrdU was visualized by
incubating the cells with mouse monoclonal anti-BrdU (Sigma) at 1/
200 dilution in phosphate-buffered saline and 1.5% normal horse
serum for 1 hour at 371C. Bound antibody was detected using the
avidin–biotin–peroxidase complex method (ABC kit, Vector, Burlin-
game, CA) and 3-amino-9-ethylcarbazole (Vector) as the chromo-
gen. Sections were counterstained with hematoxylin (Fisher,
Pittsburgh, PA). Cells were imaged through an Olympus BX41
microscope using the QFire camera and QCapture software
(Olympus, Tokyo, Japan). Four representative fields (averaging
100–200 cells each) photographed through the  10 lens were
analyzed for each of the three melanoma lines. The images were
printed on an HP color LaserJet 4600dn printer (Hewlett Packard,
Boise, ID). Nuclei were traced onto transparency film and separated
into ‘‘small’’ and ‘‘large’’ subgroups using a size template that was
created to separate the groups into roughly equal halves. This same
size template was used for all three lines. The transparencies were
then re-matched with the original prints and the red nuclei were
scored as positive. Syncytia with three or more nuclei were not
included. The standard deviation was differences in the counts on
the four representative fields.
Fontana–Masson staining
Sorted cells were affixed to Super Frost plus glass slides (Esco,
Portsmith, NH) by cytospin centrifugation, fixed in formalin, and
treated with 3.3% silver amine solution for 90 minutes at 601C, 0.2%
gold chloride for 10 minutes at room temperature, 5% sodium
thiosulfate for 5 minutes, and counterstained with nuclear fast red
(Sigma).
Fluorescence antibody staining
Primary antibodies included those targeted against nestin (3k1,
Abcam, Cambridge, MA), gp100 (NKI-beteb, Monosan-Caltag,
Burlingame, CA), mart-1 (m2-7c10/m2-7e3, Zymed, South San
Francisco, CA), smooth muscle actin (Sigma), and NGFR (C40-
1457, PE labeled, BD Pharmingen, San Diego, CA). Secondary
antibodies were anti-IgG1, IgG2a, and IgG2b (FITC, Cy3-labeled Cal
Tag). Cells were fixed in 4% paraformaldehyde and permeabilized
with 0.1% Triton. Cells were stained with primary antibodies (1:100)
for 45 minutes at room temperature and secondary antibodies
(1:400) for 20 minutes at room temperature in 1.5% horse serum
and 1% bovine serum albumin in phosphate-buffered saline. The
nuclei were counterstained with Hoechst 33342 dye (1 mg/ml).
Negative controls were handled identically but lacked the primary
antibodies. The stained cells were imaged on Olympus BX41
microscope using the QFire camera and QCapture software
(Olympus). Photoshop elementss software was used to adjust
brightness and contrast and to overlay the individual color images
into multicolor composites.
Murine window
The murine window experiments were carried out under an
approved Institutional Animal Care and Use Committee (IACUC)
protocol. Nude mice (NCI, Frederick, MD) were utilized for these
studies. The surgical technique and placement of the window
devices was carried out as described previously (Shan et al., 2004).
Melanoma cells were sorted by flow cytometry, pelleted, and
resuspended in media at a concentration of 1 106 cells/ml.
Approximately 40 ml was injected into the murine skin and then
covered with a clear coverglass insert. At follow-up time points, the
tissue was examined through the coverglass on a Carl Zeiss MPS
intravital microscope and the cells/tumor imaged as previously
described (Shan et al., 2004).
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